June 2019 - Volume 3 - Issue S1 - Contributor Index

PS1351 CRITICAL ANALYSIS OF THE STRINGENT COMPLETE RESPONSE IN MULTIPLE MYELOMA. AN UPDATED OF THE ANALYSIS BASED ON THE PETHEMA/GEM2012MENOS65 PHASE III CLINICAL TRIAL

Ubieto, A. Jiménez; Martinez-Lopez, J.; Paiva, B.; More

HemaSphere. 3(S1):617, June 2019.

Author:
Ucar, M.A.
Author:
Uccella, S.

PS1319 MYD88L265P MUTATION IN WM AND IGM-MGUS: COMPARISON OF FEASIBILITY AND BENEFIT BETWEEN DDPCR AND STANDARD ASQPCR IN CD19+ SELECTED AND UNSELECTED SAMPLES

Drandi, D.; Furlan, D.; Ferrante, M.; More

HemaSphere. 3(S1):602, June 2019.

Author:
Uchida, N.
Author:
Uchimaru, K.
Author:
Uchino, K.

PF756 DONOR UNC-93 HOMOLOG B1 GENETIC VARIATION PREDICTS SURVIVAL OUTCOMES AFTER UNRELATED BONE MARROW TRANSPLANTATION

Uchino, K.; Mizuno, S.; Horio, T.; More

HemaSphere. 3(S1):332, June 2019.

Author:
Uchino, Y.

PB2055 HIGH PREVALENCE OF NON-GERMINAL CENTER B-CELL PHENOTYPE WITH MYC OVEREXPRESSION IN JAPANESE PATIENTS WITH INTRAVASCULAR LARGE B-CELL LYMPHOMA

Takahashi, H.; Nakanishi, Y.; Miura, K.; More

HemaSphere. 3(S1):927, June 2019.

Author:
Uchiyama, H.
Author:
Uchiyama, M.

PF623 PHASE 1/2 STUDY OF ISATUXIMAB MONOTHERAPY FOR RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA IN JAPANESE PATIENTS

Iida, S.; Sunami, K.; Ri, M.; More

HemaSphere. 3(S1):265, June 2019.

Author:
Uchiyama, T.
Author:
Uda, S.
Author:
Ueda, T.
Author:
Ueda, Y.

S135 NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3(S1):19-20, June 2019.

PS1115 THE RELATIONSHIP BETWEEN THE PRETREATMENT PNH CLONE SIZE AND CLINICAL COURSE IN PATIENTS WITH BONE MARROW FAILURE SYNDROMES: INTERIM ANALYSIS OF JAPANESE MULTICENTER PROSPECTIVE STUDY

Ueda, Y.; Hosokawa, K.; Ishiyama, K.; More

HemaSphere. 3(S1):504-505, June 2019.

PS1344 PHASE 1/2 STUDY OF DSP-7888 IN PATIENTS WITH HIGHER-RISK (HR) MYELODYSPLASTIC SYNDROMES (MDS) AFTER FAILURE OF AZACITIDINE (AZA) THERAPY

Usuki, K.; Ueda, Y.; Fujita, J.; More

HemaSphere. 3(S1):613-614, June 2019.

Author:
Uemura, S.
Author:
Ueno, H.

PF301 REDUCED-INTENSITY IMMUNOCHEMOTHERAPY WITHOUT VINCRISTINE IN ELDERLY PATIENTS OLDER THAN 80 YEARS OLD WITH DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTRE, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL

Yoshida, I.; Suehiro, Y.; Hirabayashi, Y.; More

HemaSphere. 3(S1):102-103, June 2019.

PF532 INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3(S1):218-219, June 2019.

PS1367 COMPREHENSIVE GENETIC ANALYSIS OF MULTIPLE MYELOMA IN JAPAN

Kanamori, T.; Sanada, M.; Ri, M.; More

HemaSphere. 3(S1):624-625, June 2019.

Author:
Ufkin, M.

S868 EMERGING CLINICAL ACTIVITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY (AB), IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)

Bannerji, R.; Arnason, J.; Advani, R.; More

HemaSphere. 3(S1):388-389, June 2019.

Author:
Ugalde, L.

PS1209 NKG2D AND BCMA-CAR NK CELLS EFFICIENTLY ELIMINATE MULTIPLE MYELOMA CELLS. A COMPREHENSIVE COMPARISON BETWEEN TWO CLINICALLY RELEVANT CARS

Maroto-Martín, E.; Encinas, J.; García-Ortiz, A.; More

HemaSphere. 3(S1):550-551, June 2019.

Author:
Ugo, V.

PS1472 CURRENT PRACTICE IN THE MANAGEMENT OF ESSENTIAL THROMBOCYTEMIA AND POLYCYTHEMIA VERA: A SURVEY FROM THE FRENCH INTERGROUP OF MYELOPROLIFERATIVE NEOPLASMS (FIM) AMONG 120 HEMATOLOGISTS AND INTERNISTS

Fouquet, G.; Cony-Makhoul, P.; Dupriez, B.; More

HemaSphere. 3(S1):679, June 2019.

Author:
Uhlar, C.

PF592 IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3(S1):248-249, June 2019.

Author:
Uhlig, J.
Author:
Uhlig, K.
Author:
Uike, N.

PS1259 LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA

Ogura, M.; Yamamoto, K.; Morishima, Y.; More

HemaSphere. 3(S1):575-576, June 2019.

Author:
Ujjani, C.

PF381 FACTORS IMPACTING TREATMENT SELECTION IN TREATMENT-NAÏVE PATIENTS WITH CLL: A MULTICENTER STUDY

Rhodes, J.; Sail, K.; Sarraf Yazdy, M.; More

HemaSphere. 3(S1):142, June 2019.

Author:
Ukimeraj, A.
Author:
Ukropec, J.

PF591 EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D-RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK

Dimopoulos, M.A.; San-Miguel, J.; White, D.; More

HemaSphere. 3(S1):247-248, June 2019.

PF596 EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK

Weisel, K.; Spencer, A.; Lentzsch, S.; More

HemaSphere. 3(S1):251, June 2019.

PS1349 UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA

Mateos, M.-V.; Kumar, S.; Gonzalez, V.; More

HemaSphere. 3(S1):616, June 2019.

Author:
Ulianchenko, K.

PB1812 PHARMACO-ECONOMY ANALYSIS OF THE THREATMENT WITH R-DA-EPOCH, R-CHOP, AND CHOP-LIKE REGIMENS IN HIGH-RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (UKRAINIAN MULTICENTER STUDY)

Filonenko, K.; Kriachok, I.; Martynchyk, A.; More

HemaSphere. 3(S1):830-831, June 2019.

PB1996 PROGNOSTICATION OF HODGKIN'S LYMPHOMA BY IPET AND IPS: UPDATE DATA OF 8 HEMATOLOGICAL UKRAINIAN CENTERS.

Novosad, O.; Skrypets, T.; Pastushenko, I.; More

HemaSphere. 3(S1):903-904, June 2019.

Author:
Ulsperger, E.

PS1331 MYELOMONOCYTIC SKEWING IN CHRONIC MYELOMONOCYTIC LEUKEMIA: PHENOTYPIC, GENOTYPIC AND BIOLOGIC FEATURES AND IMPACT ON SURVIVAL

Geissler, K.; Jäger, E.; Barna, A.; More

HemaSphere. 3(S1):607-608, June 2019.

Author:
Ulu, B. Uncu
Author:
Ulusoy, Y.
Author:
Umaña, P.

PF207 TARGETING WILMS TUMOR 1 WITH A T CELL BISPECIFIC ANTIBODY (WT1-TCB): EX VIVO AND IN VIVO POTENCY BY BIVALENT RECOGNITION OF PEPTIDE-MHC COMPLEXES FROM AN INTRACELLULAR TUMOR ANTIGEN

Augsberger, C.; Klein, C.; Heitmüller, C.; More

HemaSphere. 3(S1):56, June 2019.

Author:
Umarova, B.
Author:
Umit, E.
Author:
Umlauff, L.
Author:
Ünal, A.

PB1933 CLINICAL FEATURES AND TREATMENT OUTCOMES OF CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS IN TURKEY: REAL-WORLD DATA

Saydam, G.; Ünal, A.; Kurtoglu, E.; More

HemaSphere. 3(S1):879, June 2019.

Author:
Unal, E.
Author:
Uncu Ulu, B.
Author:
Unger, T.

PF261 A RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF SELINEXOR VERSUS PHYSICIAN'S CHOICE (PC) IN OLDER PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)

Sweet, K.; Blum, W.; Donner, H.; More

HemaSphere. 3(S1):82-83, June 2019.

Author:
Ungerstedt, J.

S840 IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA – A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP

Pleyer, L.; Leisch, M.; Kouraklis, A.; More

HemaSphere. 3(S1):374-375, June 2019.

Author:
Unuvar, A.

PB1933 CLINICAL FEATURES AND TREATMENT OUTCOMES OF CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS IN TURKEY: REAL-WORLD DATA

Saydam, G.; Ünal, A.; Kurtoglu, E.; More

HemaSphere. 3(S1):879, June 2019.

Author:
Uoshima, N.

S135 NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3(S1):19-20, June 2019.

PF407 TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3(S1):155-156, June 2019.

Author:
Upasani, S.

PF383 PROGNOSTIC TESTING AND TREATMENT APPROACHES BASED ON REAL-WORLD CLINICAL EXPERIENCE FROM AN INTERIM ANALYSIS OF THE INFORMCLL REGISTRY OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

Mato, A.R.; Barrientos, J.C.; Brander, D.; More

HemaSphere. 3(S1):143-144, June 2019.

Author:
Ural, A.U.
Author:
Uranga, A.

PB2344 EVALUATION OF THE PREDICTIVE VALUE OF HEMATOPOIETIC PROGENITOR CELL COUNT IN SYSMEX XN ANALYZERS FOR CD34+ STEM CELL MOBILIZATION IN PERIPHERAL BLOOD PREVIOUS TO THE APHERESIS

Furundarena, J. R.; Ferreiro, J. J.; Alkorta, A.; More

HemaSphere. 3(S1):1044, June 2019.

PB2370 CD34+ CELL COUNT BY FLOW CYTOMETRY IS BETTER THAN HEMATOPOIETIC PROGENITOR CELL COUNT BY SYSMEX XN ANALYZERS IN SAMPLES COLLECTED PRE-APHERESIS TO PREDICT APHERESIS PRODUCT STEM CELL YIELD

Furundarena, J. R.; Uranga, A.; González, C.; More

HemaSphere. 3(S1):1055, June 2019.

Author:
Urb, M.

PS1303 CHRONIC TCR STIMULATION PROMOTES PERIPHERAL T-CELL LYMPHOMAGENESIS AND INDUCES ADDICTION TO SYK AND NK RECEPTOR SIGNALING

Carras, S.; Chartoire, D.; Marcais, A.; More

HemaSphere. 3(S1):595, June 2019.

Author:
Urbankova, H.
Author:
Urbano, M.

PS1214 INFECTIOUS COMPLICATIONS FOLLOWING ARI-0001 CELL (A3B1:CD8:4–1BB:CD3Z CART19) TREATMENT IN ADULT AND PEDIATRIC PATIENTS WITH CD19+ RELAPSED / REFRACTORY MALIGNANCIES

Ortiz-Maldonado, V.; Alonso-Saladrigues, A.; Cardozo, C.; More

HemaSphere. 3(S1):553-554, June 2019.

S1636 FRACTIONATED DOSING OF ARI-0001 CELLS (A3B1:CD8:4–1BB:CD3Z CAR19) AND EARLY TOCILIZUMAB ADMINISTRATION MAY REDUCE THE INCIDENCE OF SEVERE CYTOKINE RELEASE SYNDROME IN PATIENTS WITH CD19+ MALIGNANCIES

Ortiz-Maldonado, V.; Alonso-Saladrigues, A.; Caballero-Baños, M.; More

HemaSphere. 3(S1):756, June 2019.

Author:
Urbanova, R.
Author:
Ureshino, H.

PF407 TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3(S1):155-156, June 2019.

Author:
Uriarte, J.
Author:
Uroševic, I.
Author:
Urreta, I.

PB2370 CD34+ CELL COUNT BY FLOW CYTOMETRY IS BETTER THAN HEMATOPOIETIC PROGENITOR CELL COUNT BY SYSMEX XN ANALYZERS IN SAMPLES COLLECTED PRE-APHERESIS TO PREDICT APHERESIS PRODUCT STEM CELL YIELD

Furundarena, J. R.; Uranga, A.; González, C.; More

HemaSphere. 3(S1):1055, June 2019.

Author:
Ursu, C.E.
Author:
Ursuleac, I.
Author:
Uryu, H.
Author:
Usala, E.

S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY

Malagola, M.; Efficace, F.; Polverelli, N.; More

HemaSphere. 3(S1):396-397, June 2019.

Author:
Useir, S.